{"version":"1.0","provider_name":"Le Journal du Manager","provider_url":"https:\/\/www.manager.one\/fr\/journal","author_name":"Jos\u00e9phine","author_url":"https:\/\/www.manager.one\/fr\/journal\/author\/jcourtois\/","title":"Orakl Oncology, r\u00e9inventer le d\u00e9veloppement du m\u00e9dicament en oncologie : Rencontre avec Fanny Jaulin, CEO et CSO d\u2019Orakl Oncology Orakl Oncology : comment l\u2019IA transforme le d\u00e9veloppement du m\u00e9dicament contre le cancer","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"2bLhDYTlH2\"><a href=\"https:\/\/www.manager.one\/fr\/journal\/orakl-oncology-ia-medicament-cancer\/\">Orakl Oncology, r\u00e9inventer le d\u00e9veloppement du m\u00e9dicament en oncologie : Rencontre avec Fanny Jaulin, CEO et CSO d\u2019Orakl Oncology<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.manager.one\/fr\/journal\/orakl-oncology-ia-medicament-cancer\/embed\/#?secret=2bLhDYTlH2\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Orakl Oncology, r\u00e9inventer le d\u00e9veloppement du m\u00e9dicament en oncologie : Rencontre avec Fanny Jaulin, CEO et CSO d\u2019Orakl Oncology\u00a0\u00bb &#8212; Le Journal du Manager\" data-secret=\"2bLhDYTlH2\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/moneassets.blob.core.windows.net\/journal\/2026\/10\/Group-9-4.png","thumbnail_width":1196,"thumbnail_height":800,"description":"Orakl Oncology est une plateforme techbio fran\u00e7aise \u00e0 l\u2019intersection de la biologie et de l\u2019intelligence artificielle, qui vise \u00e0 transformer le d\u00e9veloppement du m\u00e9dicament contre le cancer. Elle r\u00e9unit aujourd\u2019hui une \u00e9quipe de 40 collaborateurs....Fanny Jaulin, CEO d\u2019Orakl Oncology, explique comment l\u2019IA et la biologie permettent de pr\u00e9dire l\u2019efficacit\u00e9 des m\u00e9dicaments contre le cancer avant leurs essais cliniques."}